Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Rectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 6Uterine Cervical Neoplasms 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Glioblastoma 4Esophageal Neoplasms 4Brain Neoplasms 4Neoplasms 3Nasopharyngeal Carcinoma 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma 2Adenocarcinoma 2Spinal Cord Neoplasms 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Rhabdomyosarcoma 1Rectal Cancer Patients 1Radiation Injuries 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pelvic Neoplasms 1

Interventions

Radiotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × HER2-Negative Locally Advanced Breast Cancer × Radiotherapy × Clear all
NCT06908668 2025-04-03

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
170 enrolled
Breast

HER2-Negative Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡